Antibiotics Partnering Terms and Agreements

PR Newswire

NEW YORK, Nov. 21, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antibiotics Partnering Terms and Agreements

http://www.reportlinker.com/p01181009/Antibiotics-Partnering-Terms-and-Agreements.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in antibiotics partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Antibiotics partnering contract documents
Top antibiotics deals by value

The Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:

Antibiotics
Aminoglycosides
Cephalosporin
Clindamycin
Macrolides
Penicillin
Quinolones
Sulfonamides
Tetracycline

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains over 180 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibiotics dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading antibiotics deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in antibiotics partnering and dealmaking since 2007.

In addition, a comprehensive appendix is provided organized by antibiotics partnering company A-Z, deal type definitions and antibiotics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibiotics technologies and products.

Antibiotics Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of antibiotic deal trends since 2007
Access to headline, upfront, milestone and royalty data
Analysis of the structure of antibiotics agreements with numerous real life case studies
Comprehensive access to over 160 actual antibiotics contracts entered into by the world's biopharma companies
Detailed access to actual antibiotics contracts enter into by the leading fifty bigpharma companies
Insight into the terms included in a antibiotics agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Antibiotics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to antibiotics trends and structure of deals entered into by leading companies worldwide.

Antibiotics Partnering Terms and Agreements includes:

Trends in antibiotics dealmaking in the biopharma industry since 2007
Analysis of antibiotics deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life antibiotics deals
Access to over 180 antibiotics contract documents
The leading antibody deals by value since 2007
Most active antibiotics dealmakers since 2007
The leading antibiotics partnering resources

In Antibiotics Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

TABLE OF CONTENTS

Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in antibiotics dealmaking
2.1. Introduction
2.2. Antibiotics partnering over the years
2.3. Bigpharma antibiotics dealmaking activity
2.4. Most active in antibiotics partnering
2.5. Antibiotics partnering by deal type
2.5. Antibiotics partnering by disease type
2.6. Partnering by antibiotics technology type
2.7. Average deal terms for antibiotics partnering
2.7.1 Antibiotics headline values
2.7.2 Antibiotics upfront payments
2.7.3 Antibiotics milestone payments
2.7.4 Antibiotics royalty rates
2.8. The anatomy of antibiotics partnering
2.9. The anatomy of antibiotics deal
2.9.a. Case study 1: Calixa Therapeutics & Astellas –May 24 2009
2.9.b. Case study 2: Advanced Life Sciences & Wyeth- Oct 1 2008
2.9.c. Case study 3: Astellas & Optimer Pharmaceuticals- Feb 7 2011
Chapter 3 – Leading antibiotics deals
3.1. Introduction
3.2. Top antibiotics deals by value
Chapter 4 – Bigpharma antibiotics deals
4.1. Introduction
4.2. How to use bigpharma antibiotics partnering deals
4.3. Big pharma antibiotics partnering company profiles
Abbott
Actavis Inc (formerly Watson Pharmaceuticals)
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Bristol-Myers Squibb
Eli Lilly
Forest Laboratories
GlaxoSmithKline
Merck & Co
Novartis
Pfizer
Sanofi
Shionogi
Warner Chilcott
Chapter 5 – Antibiotics partnering contracts directory
5.1. Introduction
5.2. Company A-Z
Ab Sciex
Abbott Laboratories
Accelr8
Accium BioSciences
ACE BioSciences
Acella Pharmaceuticals
Achaogen
Actavis
Advanced Life Sciences
Advanced Technology Company
Advancis Pharmaceutical
Affibody
Affinium Pharmaceuticals
Albany Molecular Research
Alfa Wassermann
ALK-Abello
AllerQuest
Almac Pharma Services
Alopexx
Anacor Pharmaceuticals
ARigen
Ascenion
Aspen Pharmacare
Astellas
AstraZeneca
AureoGen
AuricX Pharmaceuticals
Aurobindo Pharma
Aurospharma Company
AvidBiotics
Banyu Pharmaceutical
Basilea Pharmaceutica
Baxter Healthcare
Bayer
Beijing Med-Pharm
Beth Israel Deaconess Medical Center
BioConnections
BioCryst Pharmaceuticals
Biomedical Advanced Research and Development Authority
Brigham and Women's Hospital
Bristol-Myers Squibb
Cadila Pharmaceuticals
Calixa Therapeutics
Cardinal Health
Cempra Pharmaceutical
Center for Disease Control and Prevention
Ceragenix Pharmaceuticals
Cook Medical
Cornerstone Biopharma
Cornerstone Therapeutics
Creative Antibiotics
Cubist Pharmaceuticals
CUBRC
Cumencor Pharmaceuticals
Curetis
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation Therapeutics
D&A Pharma
Deerfield Management
Defense Threat Reduction Agency
Delphi Genetics
Department of Defense
Department of Health and Human Services
Diod
Dong-A Pharmaceutical
Dow Pharmaceutical Sciences
DPT Laboratories
Durata Therapeutics
Dynamic Microbials
E-Therapeutics
Eagle Pharmaceuticals
Eli Lilly
Embil Pharmaceuticals
Emergent BioSolutions
Enanta Pharmaceuticals
Eurofins
Eurogentec Biologics
European Commission
Families of Spinal Muscular Atrophy
Fedora Pharmaceuticals
Flamel Technologies
Flemish agency for Innovation by Science and Technology
Foamix
Food and Drug Administration (FDA)
Forest Healthcare
Forest Laboratories
Forsyth Institute
France's General Directorate for Armaments
Fundacion Medina
Galapagos
Genetics Laboratory
Glaxo Wellcome
GlaxoSmithKline
Green Cross
Grunenthal
Hainan Haiyao
Heraeus
Imaxio
Innocoll
Innovative Medicines Initiative (IMI)
Institute of Materia Medica
Intrexon
Inverness Medical Innovations
Iroko Pharmaceuticals
Johnson & Johnson
Kala Pharmaceuticals
Khandelwal Laboratores
Kringle Europe
Kringle Pharma
KV Pharmaceutical
LabCorp
Lawrence Livermore National Laboratory
Medical Research Council
MedImmune
Medivir
Merck & Co
Merus Labs International
MethylGene
Microbiotix
MicuRx Pharmaceuticals
MiddleBrook Pharmaceutical
Mylan Laboratories
Nabriva Therapeutics
NAEJA Pharmaceutical
Nanologica
NanoMR
National Heart, Lung and Blood Institute
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Nektar Therapeutics
Novalar Pharmaceuticals
Novartis
Novartis Institute for Tropical Diseases
Novozymes
Optimer Pharmaceuticals
Oragenics
Orchid Chemicals and Pharma
Oscient Pharmaceuticals
Paratek Pharmaceuticals
PATH (Appropriate Technology in Health)
Pergamum
Pernix Therapeutics
Perrigo
Pfizer
PharmaSwiss
Phenomenex
Pherecydes Pharma
Phico Therapeutics
Phosphagenics
Phylogica
PluroGen Therapeutics
Polymedix
Prev AbR
Prolysis
Proteo Biotech
Quotient Bioresearch
RaQualia Pharma
Replidyne
Research Council of Norway
Rib-X Pharmaceuticals
Salix Pharmaceuticals
Sanofi-Aventis
Sanofi
Savara Pharma
Sequella
Shanghai Knowshine
Shanghai MengKe Pharmaceuticals
Shanghai Zhangjiang Biomedical Industry Venture Capital
Shanglian Biochemical Medicine
Shionogi
Sichuan Jiangchuan Pharmaceutical
Sichuan Mingxin Pharmaceutical
SINTEF
SJ Pharmaceuticals
Skinvisible
SRI International
Statens Serum Institute
Stemgent
Stratos Group
Strides Arcolab
Summit
Swedish Orphan Biovitrum
Swedish University of Agricultural Sciences
Synthetic Biologics
TaiGen Biotechnology
Takara Bio
TB Alliance
TET Systems
Tetraphase Pharmaceuticals
Tianyin Pharmaceutical
Tongli Pharmaceuticals
Transave
TransPerfect Trial Interactive
Tripep
Trius Therapeutics
University of North Carolina
US Army Medical Research Institute of Infectious Diseases
Vicuron
Walter Reed Army Institute of Research
Warner Chilcott
Wellcome Trust
Wyeth
Xellia Pharmaceuticals
Yissum Research Development
Zhejiang Medicine
5.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Manufacturing - OEM
Marketing
Option
Research
Royalty financing
Supply
Termination
Warranty
5.4. By stage of development
Discovery
Marketed
Formulation
Phase I
Phase II
Phase III
Preclinical
Regulatory
5.5. By therapy area
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Oncology
Psychiatry
Public Health
Respiratory
Sexual Health
Chapter 6 – Antibiotics dealmaking by technology type
6.1. Introduction
6.2. Deals by antibiotics type
Antibiotics
Appendix – Antibiotics partnering resource center
Online antibiotics partnering
Antibiotics partnering events
Further reading on antibiotics dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

Table of figures


Figure 1: Antibiotics partnering since 2007
Figure 2: Bigpharma – top 50 – antibiotics deals 2007 to 2013
Figure 3: Bigpharma antibiotics deal frequency – 2007 to 2013
Figure 4: Active antibiotics dealmaking activity– 2007 to 2013
Figure 5: Antibiotics partnering by deal type since 2007
Figure 7: Antibiotics partnering by disease type since 2007
Figure 9: Antibiotics partnering by technology type since 2007
Figure 8: Antibiotics deals with a headline value
Figure 9: Antibiotics deal headline value distribution, US$million – discovery stage
Figure 10: Antibiotics deal headline value distribution, US$million – preclinical stage
Figure 11: Antibiotics deal headline value distribution, US$million – phase I stage
Figure 12: Antibiotics deal headline value distribution, US$million – phase II stage
Figure 13: Antibiotics deal headline value distribution, US$million – phase III stage
Figure 14: Antibiotics deal headline value distribution, US$million – regulatory stage
Figure 15: Antibiotics deal headline value distribution, US$million – marketed stage
Figure 16: Summary median headline value by stage of development, 2007-2013
Figure 17: Antibiotics deals with upfront payment values
Figure 18: Antibiotics deal upfront payment distribution, US$million – discovery stage
Figure 19: Antibiotics deal upfront payment distribution, US$million – preclinical stage
Figure 20: Antibiotics deal upfront payment distribution, US$million – phase I stage
Figure 21: Antibiotics deal upfront payment distribution, US$million – phase II stage
Figure 22: Antibiotics deal upfront payment distribution, US$million – phase III stage
Figure 23: Antibiotics deal upfront payment distribution, US$million – regulatory stage
Figure 24: Antibiotics deal upfront payment distribution, US$million – marketed stage
Figure 25: Summary median upfront payments by stage of development, 2007-2013
Figure 26: Antibiotics deals with milestone payments
Figure 27: Antibiotics deal milestone distribution, US$million – discovery stage
Figure 28: Antibiotics deal milestone distribution, US$million – preclinical stage
Figure 29: Antibiotics deal milestone distribution, US$million – phase I stage
Figure 30: Antibiotics deal milestone distribution, US$million – phase II stage
Figure 31: Antibiotics deal milestone distribution, US$million – phase III stage
Figure 32: Antibiotics deal milestone distribution, US$million – regulatory stage
Figure 33: Antibiotics deal milestone distribution, US$million – marketed stage
Figure 34: Antibiotics deals with royalty rates, %
Figure 35: Antibiotics deal royalty rate distribution, US$million – discovery stage
Figure 36: Antibiotics deal royalty rate distribution, US$million – preclinical stage
Figure 37: Antibiotics deal royalty rate distribution, US$million – phase I stage
Figure 38: Antibiotics deal royalty rate distribution, US$million – phase II stage
Figure 39: Antibiotics deal royalty rate distribution, US$million – phase III stage
Figure 40: Antibiotics deal royalty rate distribution, US$million – regulatory stage
Figure 41: Antibiotics deal royalty rate distribution, US$million – marketed stage
Figure 42: Summary median royalty rate by stage of development, 2007-2013
Figure 43: Components of the typical antibiotics deal structure
Figure 44: Top antibiotics deals by value since 2007
Figure 45: Online partnering resources
Figure 46: Forthcoming partnering events

Companies mentioned

Abbott Japan

Abbott Laboratories

Abraxis BioScience

ACADIA Pharmaceuticals

Acceleron Pharma

Achillion Pharmaceuticals

Adnexus Therapeutics

Adolor

AEterna Zentaris

Affymax

Agensys

Alfacell

Allergan

Ambit Biosciences

Amgen

Amylin Pharmaceuticals

Anacor Pharmaceuticals

Anesiva

Archemix

Ariad Pharmaceuticals

ArQule

Array Biopharma

ARYx Therapeutics

Astellas Pharma

AstraZeneca

Athersys

Atley Pharmaceuticals

Auriga Laboratories

Aventis

AVEO Pharmaceuticals

Barrier Therapeutics

Bayer

Biogen Idec

BioMarin Pharmaceuticals

BioMerieux

Biovail

Boehringer Ingelheim

Bristol-Myers Squibb

Cardiome Pharma

Celgene

Cell Genesys

Cepheid

ChemoCentryx

Cornerstone Biopharma

Cortex Pharmaceuticals

Critical Therapeutics

Cubist Pharmaceuticals

CV Therapeutics

Cypress Bioscience

Cytokinetics

Daiichi Sankyo

DepoMed

Dey Pharma

DoctorDirectory

DOR BioPharma

Dyax

Dynavax Technologies

Eisai

Eli Lilly

Enanta Pharmaceuticals

Endo Pharmaceuticals

Exelixis

Facet Biotechnology

Forest Laboratories

Forest Pharmaceuticals

Galderma

Genentech

Genzyme

Gilead Sciences

GlaxoSmithKline

GTx

Hyperion Therapeutics

ImmunoGen

Immunomedics

Impax Laboratories

Incyte

Inspire Pharmaceuticals

InterMune

InVentiv Health

Ipsen

Ironwood Pharmaceuticals

Janssen Research & Development

KaloBios Pharmaceuticals

La Jolla Pharmaceutical

Macrogenics

MAP Pharmaceuticals

Maxygen

Medivation

Menarini

Merck and Co

Merck KGaA

Merck Sharpe & Dohme

Merrimack Pharmaceuticals

Metabasis Therapeutics

Micromet

MiddleBrook Pharmaceutical

Millennium

Mylan Laboratories

Nektar Therapeutics

Novartis

Novartis Consumer Health

Novo Nordisk

Nycomed

OncoGenex Pharmaceuticals

Optimer Pharmaceuticals

Orexigen Therapeutics

Ortho Biotech

Par Pharmaceutical

PDL BioPharma

Pfizer

PhotoMedex

Procter & Gamble

Procter & Gamble Pharmaceuticals

Purdue Pharma

Regeneron Pharmaceuticals

Rib-X Pharmaceuticals

Roche

Sagent Pharmaceuticals

Salix Pharmaceuticals

Sanofi-Aventis

Sanofi-Pasteur

Sanofi

Santarus

Schering-Plough

Seattle Genetics

Serono

Sigma-Tau

Solvay

Somaxon Pharmaceuticals

Spectrum Pharmaceuticals

Strativa Pharmaceuticals

Sucampo Pharmaceuticals

Synta Pharmaceuticals

Takeda Pharmaceutical

TAP Pharmaceutical

Targacept

Tercica

Teva Pharmaceuticals

Tibotec

Transcept Pharmaceuticals

Ucyclyd Pharma

Valeant Pharmaceuticals

Veracyte

Vernalis

Vical

Victory Pharma

Warner Chilcott

Watson Pharmaceuticals

Wyeth

Xenoport

Zogenix

ZymoGenetics

To order this report: Antibiotics Partnering Terms and Agreements
http://www.reportlinker.com/p01181009/Antibiotics-Partnering-Terms-and-Agreements.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Rates

View Comments (0)